LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells

    Piergiuseppe De Rosa / Federica Severi / Suleman Khan Zadran / Marco Russo / Sara Aloisi / Alberto Rigamonti / Giovanni Capranico / Giorgio Milazzo / Giovanni Perini

    International Journal of Molecular Sciences, Vol 24, Iss 5408, p

    2023  Volume 5408

    Abstract: Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB’s mutation landscape, optimizing individualized therapies is still challenging. In the context of genomic alterations, MYCN ... ...

    Abstract Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB’s mutation landscape, optimizing individualized therapies is still challenging. In the context of genomic alterations, MYCN amplification is the most correlated event with poor outcomes. MYCN is involved in the regulation of several cellular mechanisms, including cell cycle. Thus, studying the influence of MYCN overexpression in the G1/S transition checkpoint of the cell cycle may unveil novel druggable targets for the development of personalized therapeutical approaches. Here, we show that high expression of E2F3 and MYCN correlate with poor prognosis in NB despite the RB1 mRNA levels. Moreover, we demonstrate through luciferase reporter assays that MYCN bypasses RB function by incrementing E2F3-responsive promoter activity. We showed that MYCN overexpression leads to RB inactivation by inducing RB hyperphosphorylation during the G1 phase through cell cycle synchronization experiments. Moreover, we generated two MYCN -amplified NB cell lines conditionally knockdown (cKD) for the RB1 gene through a CRISPRi approach. Indeed, RB KD did not affect cell proliferation, whereas cell proliferation was strongly influenced when a non-phosphorylatable RB mutant was expressed. This finding revealed the dispensable role of RB in regulating MYCN -amplified NB’s cell cycle. The described genetic interaction between MYCN and RB1 provides the rationale for using cyclin/CDK complexes inhibitors in NBs carrying MYCN amplification and relatively high levels of RB1 expression.
    Keywords Neuroblastoma ; MYCN ; RB ; E2F ; palbociclib ; ribociclib ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 570
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Targeting Oncogenic Transcriptional Networks in Neuroblastoma

    Roberto Ciaccio / Piergiuseppe De Rosa / Sara Aloisi / Marta Viggiano / Leonardo Cimadom / Suleman Khan Zadran / Giovanni Perini / Giorgio Milazzo

    International Journal of Molecular Sciences, Vol 22, Iss 12883, p

    From N-Myc to Epigenetic Drugs

    2021  Volume 12883

    Abstract: Neuroblastoma (NB) is one of the most frequently occurring neurogenic extracranial solid cancers in childhood and infancy. Over the years, many pieces of evidence suggested that NB development is controlled by gene expression dysregulation. These ... ...

    Abstract Neuroblastoma (NB) is one of the most frequently occurring neurogenic extracranial solid cancers in childhood and infancy. Over the years, many pieces of evidence suggested that NB development is controlled by gene expression dysregulation. These unleashed programs that outline NB cancer cells make them highly dependent on specific tuning of gene expression, which can act co-operatively to define the differentiation state, cell identity, and specialized functions. The peculiar regulation is mainly caused by genetic and epigenetic alterations, resulting in the dependency on a small set of key master transcriptional regulators as the convergence point of multiple signalling pathways. In this review, we provide a comprehensive blueprint of transcriptional regulation bearing NB initiation and progression, unveiling the complexity of novel oncogenic and tumour suppressive regulatory networks of this pathology. Furthermore, we underline the significance of multi-target therapies against these hallmarks, showing how novel approaches, together with chemotherapy, surgery, or radiotherapy, can have substantial antineoplastic effects, disrupting a wide variety of tumorigenic pathways through combinations of different treatments.
    Keywords neuroblastoma ; oncogene ; tumour suppressor ; regulatory network ; gene expression ; MYCN ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 570
    Language English
    Publishing date 2021-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma

    Ling Tao / Mahmoud A. Mohammad / Giorgio Milazzo / Myrthala Moreno-Smith / Tajhal D. Patel / Barry Zorman / Andrew Badachhape / Blanca E. Hernandez / Amber B. Wolf / Zihua Zeng / Jennifer H. Foster / Sara Aloisi / Pavel Sumazin / Youli Zu / John Hicks / Ketan B. Ghaghada / Nagireddy Putluri / Giovanni Perini / Cristian Coarfa /
    Eveline Barbieri

    Nature Communications, Vol 13, Iss 1, Pp 1-

    2022  Volume 17

    Abstract: Half of high-risk neuroblastoma patients have MYCN amplification. Here, the authors show that MYCN induces fatty acid uptake and synthesis to support neuroblastoma and inhibition of a fatty acid transporter impairs tumor progression in preclinical models. ...

    Abstract Half of high-risk neuroblastoma patients have MYCN amplification. Here, the authors show that MYCN induces fatty acid uptake and synthesis to support neuroblastoma and inhibition of a fatty acid transporter impairs tumor progression in preclinical models.
    Keywords Science ; Q
    Language English
    Publishing date 2022-06-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting

    Silvia Pomella / Matteo Cassandri / Lucrezia D’Archivio / Antonella Porrazzo / Cristina Cossetti / Doris Phelps / Clara Perrone / Michele Pezzella / Antonella Cardinale / Marco Wachtel / Sara Aloisi / David Milewski / Marta Colletti / Prethish Sreenivas / Zoë S. Walters / Giovanni Barillari / Angela Di Giannatale / Giuseppe Maria Milano / Cristiano De Stefanis /
    Rita Alaggio / Sonia Rodriguez-Rodriguez / Nadia Carlesso / Christopher R. Vakoc / Enrico Velardi / Beat W. Schafer / Ernesto Guccione / Susanne A. Gatz / Ajla Wasti / Marielle Yohe / Myron Ignatius / Concetta Quintarelli / Janet Shipley / Lucio Miele / Javed Khan / Peter J. Houghton / Francesco Marampon / Berkley E. Gryder / Biagio De Angelis / Franco Locatelli / Rossella Rota

    Nature Communications, Vol 14, Iss 1, Pp 1-

    2023  Volume 23

    Abstract: Abstract Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor ... ...

    Abstract Abstract Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor MYOD that, whilst essential for survival, cannot support differentiation. Here we discover SKP2, an oncogenic E3-ubiquitin ligase, as a critical pro-tumorigenic driver in FN-RMS. We show that SKP2 is overexpressed in RMS through the binding of MYOD to an intronic enhancer. SKP2 in FN-RMS promotes cell cycle progression and prevents differentiation by directly targeting p27Kip1 and p57Kip2, respectively. SKP2 depletion unlocks a partly MYOD-dependent myogenic transcriptional program and strongly affects stemness and tumorigenic features and prevents in vivo tumor growth. These effects are mirrored by the investigational NEDDylation inhibitor MLN4924. Results demonstrate a crucial crosstalk between transcriptional and post-translational mechanisms through the MYOD-SKP2 axis that contributes to tumorigenesis in FN-RMS. Finally, NEDDylation inhibition is identified as a potential therapeutic vulnerability in FN-RMS.
    Keywords Science ; Q
    Subject code 570
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top